Tetrahedron Letters 61 (2020) 151861

Contents lists available at ScienceDirect

Tetrahedron Letters

journal homepage: www.elsevier.com/locate/tetlet

Novel furoquinolinones from an Indonesian Plant, *Lunasia amara*

Masaki Yamashita [a], Yohei Saito [a], Abdul Rahim [a,b], Shuichi Fukuyoshi [a], Katsunori Miyake [c], Masuo Goto [d], Kyoko Nakagawa-Goto [a,d,*]

[a] School of Pharmaceutical Sciences, College of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa 920-1192, Japan
[b] Department of Pharmacognosy-Phytochemistry, Faculty of Pharmacy, Hasanuddin University, Makassar, Indonesia
[c] School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Hachioji, Tokyo 192-0392, Japan
[d] UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599-7568, USA

A R T I C L E   I N F O

Article history:
Received 3 February 2020
Revised 19 March 2020
Accepted 21 March 2020
Available online 23 March 2020

Keywords:
Lunasia amara
Furoquinolones
Structure elucidation
Antiproliferative activity

A B S T R A C T

Two new furanoquinolones, 3-oxolunacrine (**1**) and 2,3-dehydrolunacrine (**2**), and 22 known quinolones (**3–24**) were isolated from the methanol extract of the bark of *Lunasia amara*. The chemical structures of the newly isolated compounds were elucidated from HRMS and various NMR spectroscopic data. Pure (*S*)- and (*R*)-isomers of **1**, which was obtained as a racemate, were separated by chiral column chromatography. The possibility that racemic **1** occurs naturally was discussed based on a proposed biosynthetic pathway. Selected isolated quinoline alkaloids were evaluated for antiproliferative activities against five human tumor cell lines, including a multidrug-resistant cell line overexpressing p-glycoprotein.
© 2020 Elsevier Ltd. All rights reserved.

Introduction

Indonesia is a megadiversity country [1] located in one of the world's rainforest areas. Its 17,000 islands have various types of habitats and an extremely complicated geological history [2]. The additional factors of biogeography, ecology, and climate have evolved megadiverse flora leading to a large total number of plant species, including a significant percentage of endemic ones. Accordingly, Indonesia has the second largest number of traditional medicinal plants after the Amazon area [3]. Unfortunately, these diverse species, which present significant pharmaceutical research opportunities, may be lost before they are even discovered or explored scientifically. Thus, the study of the constituents found in Indonesian plants is phytochemically important.

Lunasia amara (Rutaceae) has been used as an Indonesian medicinal plant to treat skin diseases, eye irritation, and bacterial infections, as well as an aphrodisiac. Previous research revealed that *L. amara* contains several quinoline alkaloids, such as lunacrine, lunasine [4], lunacridine, lunamarine [5], lunidine, lunidonine [6], and related derivatives [7–12], which are characteristically found in the family Rutaceae. Surprisingly, after a report in 1960 [10,11], no phytochemical research on this species was reported until 2011 [12], although several biological studies using extracts of this species were published [13–20]. Our in-house evaluation indicated that a MeOH extract of *L. amara* showed 30–80% growth inhibitory effects against several chemosensitive human tumor cell lines at a concentration of 20 μg/mL. As part of our continuing phytochemical study of Indonesian plants [21], herein we describe the isolation of new furoquinolones and other known secondary metabolites from *L. amara*. Their antiproliferative effects against several human tumor cell lines are also reported.

The bark of *L. amara*, which was collected from the South Sulawesi Province in Indonesia in May 2015, was extracted with MeOH. The MeOH extract was partitioned between *n*-hexane and H_2O, which was further partitioned between ethyl acetate and H_2O. The organic phase was subjected to various types of column chromatography to yield novel furoquinoline alkaloids **1** and **2** (Fig. 1) along with known quinoline alkaloids **3–24** (Fig. 2), of which all spectrometric and spectroscopic data were identical to those reported [22–38].

Compound **1** was obtained as a colorless oil. Its molecular formula, $C_{16}H_{17}NO_4$, was suggested from the $[M + H]^+$ peak at m/z 288.1231 (calcd. for 288.1236) found in the HRFABMS spectrometric data. The ^{13}C NMR spectroscopic data also indicated the presence of 16 carbons, including two ketone carbonyl carbons at δ_c 192.5 and 172.0, a strongly deshielded quaternary carbon at δ_c 174.5, six aromatic carbons at δ_c 150.5 (deshielded by OMe), 129.6 (two overlapped carbons confirmed by HMBC correlations

* Corresponding author at: School of Pharmaceutical Sciences, College of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa 920-1192, Japan.
E-mail address: kngoto@p.kanazawa-u.ac.jp (K. Nakagawa-Goto).

https://doi.org/10.1016/j.tetlet.2020.151861
0040-4039/© 2020 Elsevier Ltd. All rights reserved.



Fig. 1. New furoquinolines **1** and **2** isolated from the bark of *L. amara*.

of H-6/H-7 with δ_c 129.6), 125.5, 120.1, and 116.1, a *O*-methyl carbon at δ_c 56.6, a *N*-methyl carbon at δ_c 36.2, two methine carbons at δ_c 91.4 (oxymethine deshielded by a neighboring ketone) and 30.3, and two sp^3 methyl carbons at δ_c 18.9 and 15.3 (Table 1). The ^{1}H NMR spectrum showed three aromatic protons at δ_H 8.11 (dd, *J* = 7.9, 1.5 Hz), 7.35 (t, *J* = 7.9 Hz), and 7.21 (dd, *J* = 7.9, 1.5 Hz), four methyl protons at δ_H 4.04, 3.97 (s, *N*-CH_3 and *O*-CH_3, respectively), 1.21, and 0.93 (both d, *J* = 6.9 Hz), as well as two methine protons at δ_H 4.62 (d, *J* = 3.6 Hz) and 2.46 (dsep, *J* = 6.9 and 3.6 Hz). A quinoline skeleton was constructed based on HMBC correlations between H-6 and C-4a/C-8, H-5 and C-4/C7, H-7 and C-8a, as well as *N*-CH_3 and C-8a/9a. Subsequently, the position of the methoxy group was determined by a HMBC correlation between *O*-CH_3 and C-8 (Fig. 3). Further HMBC and ^{1}H-^{1}H COSY analyses revealed the presence and location of an isopropyl group at C-2. The NMR data of **1** were similar to those of (−)-lunacrine (**3**),[22] except for the differences consistent with the presence of a ketone at C-3 in **1**. In the ^{1}H NMR spectra, different coupling constants were found between H-2 and H-1′, *J* = 3.6 Hz for **1** and *J* = 6.5 Hz for **3**. This dissimilarity was explained by a difference in the dihedral angle, which was affected by the substituent at C-3. The coupling constants obtained by density functional theory (DFT) calculations, *J* = 3.2 Hz for **1** and *J* = 6.4 Hz for **3**, were consistent with the experimental findings (Fig. S15, ESI). Based on all of the data, compound **1** was characterized as 3-oxolunacrine. The optical rotation and CD data implied that **1** was a racemate. Chiral column chromatography was used to separate the enantiomers, (−)-**1a** and (+)-**1b**. The value of both specific rotations was identical. The absolute configurations of (−)-**1a** and (+)-**1b** were tentatively determined by comparison with the specific rotation of the related levorotatory compound **3** (Fig. 4), since comparison of the measured ECD and the calculated one did not provide meaningful results.

The presence of a natural racemate in *L. amara* seems unusual, because all related quinoline alkaloids isolated from this genus are optically active with the same absolute configuration at C-2. This phenomenon can also be found elsewhere in the family Rutaceae, although myrtopsine[39] isolated from *Myrtopsis sellingii* (Rutaceae) has the inverted absolute configuration at C-2. The stereochemistry could be explained by the postulated biosynthetic pathway (Fig. 5). An asymmetric epoxidation occurs after the attachment of a prenyl group to a quinolinone skeleton produced from anthranilic acid. The resulting optically active epoxide **A** can serve as a common biosynthetic intermediate for all quinoline alkaloids found in *L. amara*. Compounds **4** and **6** could be biosynthesized enantioselectively *via* the cyclization indicated by the red arrows to form a dihydrofuran ring. Subsequent dehydration and reduction would give the optically active compounds **3** and **5**. If compound **1** is formed through this pathway, the isolated **1** should be chiral and, thus, the racemization might occur during the purification process. In fact, the pure (+)-**1b** was racemized in the presence of SiO_2/MeOH at room temperature. However, we cannot eliminate the possibility of racemic **1** being naturally produced through other biosynthetic pathways, such as routes I or II.



	R1	R2	R3	R4	R5
13	OCH3	H	H	H	CH3
14	H	H	H	H	CH3
15	OCH3	H	H	H	H
16	H	H	H	H	H
17	H	OCH3	OCH3	H	H
18	OCH3	H	H	A	CH3
19	-OCH2O-		H	A	CH3
20	OCH3	H	H	B	CH3
21	OCH3	H	H	C	CH3
22	-OCH2O-		H	C	CH3
23	OCH3	H	H	D	CH3
24	-OCH2O-		H	D	CH3

Fig. 2. Known quinolone alkaloids isolated from *L. amara*.

Table 1
^{1}H and ^{13}C NMR spectroscopic data of **1** and **2**.

Position	**1** ($CDCl_3$) δ_H (*J* in Hz) [a]	δ_C	**2** ($CDCl_3$) δ_H (*J* in Hz) [a]	δ_C
2	4.62, d (3.6)	91.4		157.7
3		192.5	6.64, d (1.0)	100.2
3a		101.1		107.4
4		172.0		172.5
4a		129.6		127.9
5	8.11, dd (7.9, 1.5)	120.1	8.21, dd (7.9, 1.4)	119.5
6	7.35, t (7.9)	125.5	7.28, t (7.9)	122.7
7	7.21, dd (7.9, 1.5)	116.1	7.16, dd (7.9, 1.4)	113.7
8		150.5		150.4
8a		129.6		129.6
9a		174.5		156.7
1′	2.46, dd (6.9, 3.6)	30.3	3.03, dd (6.9, 1.0)	27.8
2′	1.21, d (6.9)	18.9	1.34, d (6.9)	20.7
3′	0.93, d (6.9)	15.3	1.34, d (6.9)	20.7
OCH_3-8	3.97, s	56.6	3.96, s	56.5
NCH_3-9	4.04, s	36.2	4.21, s	37.1

[a] ^{1}H NMR: 600 MHz, ^{13}C NMR: 150 MHz in $CDCl_3$.



Fig. 3. Selected HMBC, ^{1}H–^{1}H COSY, and NOESY correlations of **1** and **2**.



Fig. 4. The stereochemical study of compound **1**.

In a previously proposed biosynthetic pathway to **8**, compounds **9** and **10** are produced through the oxidation of **8** [40–42]. However, the oxygenation of ring-A may occur after the construction of the quinolinone skeleton, since compounds **13**–**17** were isolated from this plant.

Compound **2** was obtained as a colorless amorphous solid. Its molecular formula, $C_{16}H_{17}NO_3$, was deduced from the $[M + H]^+$ peak at *m/z* 272.1284 (calcd. for 272.1287) found in HRFABMS spectrometric data, consistent with the loss of an oxygen and a hydrogen from that of **1**. The ^{1}H- and ^{13}C NMR spectra of **2** were



Fig. 5. Proposed systematic biosynthetic pathway to quinoline alkaloids from *L. amara*.

quite similar to those of **1**; however, the appearance of a proton signal at δ_H 6.64 for H-3 was accompanied by the loss of the proton signal for H-2 as well as corresponding changes in the chemical shifts of C-2 and C-3 (Table 1). These results suggested that a double bond is present between C-2 and C-3. The HMBC, ^1H–^1H COSY, and NOESY correlations (Fig. 3) supported the structural assignment of **2** as 2,3-dehydrolunacrine.

Compounds **3**, **4**, **6**, **8**, **9**, **12–14**, **16**, **17**, and **21–24**, which were isolated in sufficient quantity, were evaluated for antiproliferative activities against the following human tumor cell lines: lung carcinoma (A549), epidermoid carcinoma (KB, Hela derivative), vincristine-resistant KB subline with p-gp overexpressing (KB-VIN), triple-negative breast cancer (MDA-MB-231), and estrogen receptor-positive breast cancer (MCF-7) [43]. None of them showed

significant antiproliferative activity, suggesting that they would be nontoxic.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

We appreciate valuable comments, suggestions, and editing on the manuscript by Dr. Susan L. Morris-Natschke (UNC-CH). This study was supported by a Grant-in-Aid from the Ministry of Education, Culture, Sports, Science and Technology (MEXT KAKENHI, Japan) awarded to K.N.G. (Grant Number 16H05811). The authors thank the Indonesia Endowment Fund for Education and Ministry of Research, Technology and Higher Education of Indonesia for the BUDI-LN scholarship grant awarded to A.R.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.tetlet.2020.151861.

References

[1] Mittermeier RA. Primate, Diversity and the Tropical Forest: Case Studies from Brazil and Madagascar and the Importance of the Megadiversity Countries. in Biodiversity, O.) (National Academy Press, 1988.
[2] M. Bruyn, B. Stelbrink, R.J. Morley, R. Hall, G.R. Carvalho, C.H. Cannon, G. den Bergh, E. Meijaard, I. Metcalfe, L. Boitani, L. Maiorano, R. Shoup, T. Rintelen, Syst. Biol. 63 (2014) 879–901.
[3] Woerdenbag Elfahmi, HJ, Kayser O, J. Herb. Med. 4 (2014) 51–73.
[4] E.H. Wirth, *Lunasia amara* var. costulata, Pharmaceutisch Weekblad 68 (1931) 1011–1020.
[5] F.A. Steldt, K.K. Chen, J. Am. Pharm. Assoc. 32 (1943) 107–111.
[6] A. Ruegger, D. Stauffacher, Helv. Chim. Acta 46 (1963) 2329–2336.
[7] S. Goodwin, A.F. Smith, E.C. Horning, J. Am. Chem. Soc. 79 (1957) 2239–2241.
[8] S. Goodwin, A.F. Smith, A.A. Velasquez, E.C. Horning, J. Am. Chem. Soc. 81 (1959) 6209–6213.
[9] H.C. Beyerman, R.W. Rooda, Physical Sci. 62 (1959) 187–199.
[10] H.C. Beyerman, R.W. Rooda, Physical Sci. 63 (1960) 427–431.
[11] H.C. Beyerman, R.W. Rooda, Physical Sci. 63 (1960) 154–156.
[12] Subehan, Takahashi N, Kadota S, Tezuka Y. Phytochemistry Lett. 2011; 4: 30–33.
[13] Rahmat NR, Kamalrudin A, Sa'Ariwijaya MSF, Mat Noor M. Sains Malaysiana 2018; 47: 1109–1115.
[14] M.J. Luthfi, A. Kamalrudin, M. Noor Mat, J. Appl. Pharm. Sci. 7 (2017) 85–91.
[15] S. Hasnaeni, A. Nurrochmad, S. Widyarini, Trop. J. Pharm. Res. 16 (2017) 161–164.
[16] Takahashi N, Subehan, Kadota S, Tezuka Y. Fitoterapia 2012; 83: 774–779.
[17] Z.M. Sulaiman, S. Lallo, N. Djide, *J. Life Sci.* (Libertyville, IL, United States) 5 (2011) 639–645.
[18] M.J. Luthfi, M.M. Noor, Sains Malaysiana 38 (2009) 793–797.
[19] A.M. Aguinaldo, V.M. Dalangin-Mallari, A.P.G. Macabeo, L.T. Byrne, F. Abe, T. Yamauchi, S.G. Franzblau, Int. J. Antimicrobial Agents 29 (2007) 744–746.
[20] T.A.K. Prescott, I.H. Sadler, R. Kiapranis, S.K. Maciver, J. Ethnopharmacology 109 (2007) 289–294.
[21] A. Rahim, Y. Saito, K. Miyake, M. Goto, C.H. Chen, G. Alam, S. Morris-Natschke, K.H. Lee, K. Nakagawa-Goto, J. Nat. Prod. 81 (2018) 1619–1627.
[22] M. Sekar, K.J.R. Prasad, J. Nat. Prod. 61 (1998) 294–296.
[23] R.C. Anand, N. Selvapalam, J. Chem. Res. (1998) 6–7.
[24] N.K. Hart, J.R. Price, Aust. J. Chem. 19 (1966) 2185–2187.
[25] S.A. Barr, D.R. Boyd, N.D. Sharma, P.L. Loke, Heterocycles 79 (2009) 831–850.
[26] H. Tanaka, J.W. Ahn, M. Katayama, K. Wada, S. Marumo, Y. Osaka, Agric. Biol. Chem. 49 (1984) 2189–2190.
[27] Y.D. Min, H.C. Kwon, M.C. Yang, K.H. Lee, S.U. Choi, K.R. Lee, Arch Pharm Res. 30 (2007) 58–63.
[28] A. Ahond, F. Picot, P. Potier, C. Poupat, T. Sevenet, Phytochemistry 17 (1978) 166–167.
[29] S. Funayama, K. Murata, S. Nozoe, Phytochemistry 36 (1994) 525–528.
[30] W.E. Campbell, B. Davidowitz, G.E. Jackson, Phytochemistry 29 (1990) 1303–1306.
[31] F. Imai, K. Itoh, N. Kisibuchi, T. Kinoshita, U. Sankawa, Chem. Pharm. Bull. 37 (1989) 119–123.
[32] K. Jones, X. Roset, S. Rossiter, P. Whitfield, Org. Biomol. Chem. 1 (2003) 4380–4383.
[33] M.S. Reddy, N. Thirupathi, M.H. Babu, Eur. J. Org. Chem. (2012) 5803–5809.
[34] A.K. Chakravarty, T. Sakar, K. Masuda, K. Shiojima, Phytochemistry 50 (1999) 1263–1266.
[35] C. Ito, Y. Kondo, T.S. Wu, H. Furukawa, Chem. Pharm. Bull. 48 (2000) 65–70.
[36] C. Ito, M. Itoigawa, A. Furukawa, T. Hirano, T. Murata, N. Kaneda, Y. Hisada, K. Okuda, H. Furukawa, J. Nat. Prod. 67 (2004) 1800–1803.
[37] Sultana Atta-ur-Rahman, N, Choudhary MI, Shah PM, Khan MR. *J. Nat. Prod.* 61 (1998) 713–717.
[38] S.A. Barr, D.R. Boyd, N.D. Sharma, T.A. Evans, J.F. Malone, V.D. Mehta, Tetrahedron 50 (1994) 11219–11234.
[39] B.B. Snider, X. Wu, Heterocycles 70 (2006) 279–294.
[40] M.F. Grundon, D.M. Harrison, C.G. Spyropoulos, J. Chem. Soc. Chem. Commun. 2 (1974) 51–52.
[41] A.O. Colonna, E.G. Gros, Phytochemistry 10 (1971) 1515–1521.
[42] D.R. Boyd, N.D. Sharma, C.R. O'Dowd, J.G. Carroll, P.L. Loke, C.C.R. Allen, Chem. Commun. 31 (2005) 3989–3991.
[43] K. Miyake, C. Morita, A. Suzuki, N. Matsushita, Y. Saito, M. Goto, D.J. Newman, B.R. O'Keefe, K.H. Lee, K. Nakagawa-Goto, J. Nat. Prod. 82 (2019) 2852–2858.